Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003GlobeNewsWire • 04/01/24
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A ComebackInvestors Business Daily • 03/28/24
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsGlobeNewsWire • 03/13/24
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003GlobeNewsWire • 01/16/24
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/22/23
Solid Biosciences Provides Third Quarter Business Update and Financial ResultsGlobeNewsWire • 11/08/23
Solid Biosciences Provides Second Quarter Business Update and Financial ResultsGlobeNewsWire • 08/14/23
Solid Biosciences to Participate at the Barclays Gene Editing & Therapy SummitGlobeNewsWire • 05/22/23
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/16/23
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/11/23
Solid Biosciences Provides First Quarter Business Update and Financial ResultsGlobeNewsWire • 05/11/23
Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/21/23